Neuroleptic malignant syndrome is a rare, but potentially life-threatening adverse event associated with the use of neuroleptic agents. We describe the case of a 47-year-old schizophrenic woman who was treated with clozapine for years. The patient developed acute renal failure with pulmonary edema, and underwent mechanical ventilation and hemodialysis.
Editorial
NMS has been reported to occur at all doses and routes of administration [4] [5] [6] . Several studies have suggested that NMS is likely to occur more frequently during the initial months of treatment, after a rapid increase in dosage, or following parenteral injection [7, 8] . Studies report that NMS may occur at any time during the course of medication administration, even after a patient has been treated with the same agent, at the same dosage [2, 9] . In our patient, she has taken clozapine for years but she takes overdose with suicidal intent, overdose could able to cause NMS.
The clinical features of NMS include fever, rigidity, mental-status changes, and autonomic instability [2] . The fever is usually very high, without fluctuations, and does not respond well to antipyretics [4] . Rigidity is usually generalized and symmetric, but focal increase in muscular tone may also be present [4] . Mental status changes include delirium, changes in the level of consciousness, disorientation, and agitation. Autonomic instability presents as tachycardia and labile blood pressure [2] .
Creatine kinase elevation >10,000 IU/L is typical, and a relatively specific laboratory indicator used in the diagnosis of NMS. Increased levels of creatine kinase reflect more advanced stages of the disease and a poor prognosis [10, 11] . Other laboratory abnormalities that are commonly seen are not as specific, and include leukocytosis; elevated levels of lactate dehydrogenase, liver transaminase, and inflammatory markers such as C-reactive protein; and increased erythrocyte sedimentation rate [2, 12] .
In the present case, CK elevated upto 63,046 IU/L which implicate advanced stage and poor prognosis but finally her CK decreased to 39 IU/L and discharged alive without any persistent organ failure. Rhabdomyolysis resulting in acute renal failure with myoglobinuria may also be observed as in this case [5] .
A single presenting sign must be identified in over 80%
of cases, and NMS may occasionally have a fulminant onset [13] . Furthermore, there are no confirmed diagnostic criteria for NMS yet. A collection of detailed information about drug history coupled with laboratory abnormalities helps the clinician to arrive at a diagnosis [2] .
A broad range of disorders that manifest as fever should be considered in the differential diagnosis of NMS, and medical and neurologic evaluations are needed. To exclude primary disorders of the brain that may resemble NMS, such as structural lesions and infectious encephalitis, brain imaging studies and lumbar puncture are required [4, 12] . An electroencephalography may be needed to exclude epilepsy, in rare cases [4] . Routine muscular biopsy is not recommended for diagnosing NMS [2] .
Withholding the causative agent is the most important factor in the treatment of NMS. Other treatment options mainly comprise supportive care [2] . Therefore, a clinician should be vigilant and attempt to diagnose NMS as early as possible to consider the appropriate rationale for the interruption or continuation of neuroleptics.
In conclusion, we report a case of NMS in a patient with schizophrenia who had been on a clozapine regimen for years, without dose escalation. In this case, without a high suspicion of NMS, the patient was subject to misdiagnosis. Because of the unpredictability of NMS, when we deal with a patient who is taking neuroleptics and showing signs of NMS, we need to rule out conditions that may show similar symptoms. Clinicians should consider disorders that present similar symptoms and distinguish NMS, and thus offer appropriate care and prevent potentially fatal complications.
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